- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07900607
The Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]OD-001 in Healthy Male Participants
An Open Label, Single-Dose, Single-Period Study Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]OD-001 in Healthy Male Participants
This study looks at how the body handles an investigational drug called OD-001. Researchers want to learn how the medicine is absorbed, how it is broken down, and how it leaves the body.
About 8 healthy men will join the study, so that at least 6 people complete it. Each participant will drink a single dose of OD-001 as a liquid. This will be done on an empty stomach, so each participant will be asked not to eat for a period of time beforehand.
The medicine contains a small amount of a radioactive "tracer" (carbon-14). The tracer lets researchers follow the medicine and its breakdown products through your body. The amount of radioactivity is small and carefully limited. After the dose, researchers will collect samples such as blood, urine and stool. These will show how much of the medicine is recovered and what it turns into in the body.
Studieöversikt
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 1
Kontakter och platser
Studiekontakt
- Namn: Kelly Bourdon
- Telefonnummer: 857-393-6160
- E-post: clinicaltrials@odysseytx.com
Studieorter
-
-
-
Ruddington, Storbritannien
- Rekrytering
- Quotient Sciences
-
Kontakt:
- Study Coordinator
- Telefonnummer: +44 (0)115 974 9000
- E-post: clinicaltrials@odysseytx.com
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Aged 30 to 65 years inclusive at the time of signing informed consent
- Must agree to adhere to the contraception requirements. In addition, vasectomised male participants with partners of childbearing potential must have received medical assessment of the surgical success of the procedure Healthy male participants according to the assessment of the Investigator, as based on a complete medical history including a physical examination, vital signs, single 12-lead ECGs, and laboratory safety tests without any clinically significant abnormalities as measured at screening. ECGs and vital signs to be re-checked at pre-dose.
- Body mass index (BMI) of 18.0 to 35.0 kg/m2 as measured at screening.
- Must have regular bowel movements (i.e. average stool production of ≥1 and ≤3 stools per day).
Exclusion Criteria:
- Presence or history of clinically significant allergy requiring treatment, as judged by the Investigator. Hay fever is allowed unless it is active.
- History of clinically significant cardiovascular, renal, hepatic, dermatological, respiratory, particularly GI disease, especially peptic ulceration, clinically significant GI bleeding, UC, CD, Irritable Bowel Syndrome or malabsorption syndrome that may impair bioavailability, and neurological or psychiatric disorder
- Participants who are unable to take oral medication.
- Acute diarrhea, constipation or vomiting in the 7 days before the predicted Day 1. If screening occurs >7 days before Day 1his criterion will be determined on Day 1. Diarrhoea will be defined as the passage of liquid faeces and/or a stool frequency of greater than three times per day. Constipation will be defined as a failure to open the bowels more frequently than every other day
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Övrig
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: [14C]OD-001
oral solution |
[14C]OD-001 |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Mass balance recovery of total radioactivity in all excreta: CumAe
Tidsram: Day 1 to Day 8
|
Day 1 to Day 8
|
|
Mass balance recovery of total radioactivity in all excreta: Cum%Ae
Tidsram: Day 1 to Day 8
|
Day 1 to Day 8
|
|
Number of OD-001 metabolites at ≥10% of total exposure of [14C]-radiolabel in blood
Tidsram: Day 1 to Day 8
|
Day 1 to Day 8
|
|
Identity of OD-001 metabolites at ≥10% of total exposure of [14C]-radiolabel in blood by LC-MS and NMR
Tidsram: Day 1 to Day 8
|
Day 1 to Day 8
|
Sekundära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Rate of elimination of [14C]OD-001 in excreta by Ae
Tidsram: Day 1 to Day 8
|
Day 1 to Day 8
|
|
Rate of elimination of [14C]OD-001 in excreta by %Ae
Tidsram: Day 1 to Day 8
|
Day 1 to Day 8
|
|
Secondary Rate of elimination of [14C]OD-001 in excreta by CumAe
Tidsram: Day 1 to Day 8
|
Day 1 to Day 8
|
|
Rate of elimination of [14C]OD-001 in excreta by Cum%Ae by interval
Tidsram: Day 1 to Day 8
|
Day 1 to Day 8
|
|
Incidence of treatment-emergent adverse events
Tidsram: Day 1 to Day 8
|
Day 1 to Day 8
|
|
Percentage of [14C] total radioactivity OD-001 metabolites in excreta
Tidsram: Day 1 to Day 8
|
Day 1 to Day 8
|
|
Tmax of OD-001 in blood, total radioactivity in blood and plasma
Tidsram: Day 1 to Day 8
|
Day 1 to Day 8
|
|
Cmax of OD-001 in blood, total radioactivity in blood and plasma
Tidsram: Day 1 to Day 8
|
Day 1 to Day 8
|
|
AUC0-last of OD-001 in blood, total radioactivity in blood and plasma
Tidsram: Day 1 to Day 8
|
Day 1 to Day 8
|
|
T1/2 of OD-001 in blood, total radioactivity in blood and plasma
Tidsram: Day 1 to Day 8
|
Day 1 to Day 8
|
|
Incidence of abnormal clinical laboratory test results
Tidsram: Day 1 to Day 8
|
Day 1 to Day 8
|
|
Incidence of abnormal electrocardiograms (ECGs)
Tidsram: Day 1 to Day 8
|
Day 1 to Day 8
|
Samarbetspartners och utredare
Sponsor
Utredare
- Huvudutredare: Sharan Sidhu, MBChB, BAO, MRCS, MFPM, Quotient Sciences
- Studierektor: Anthony Opipari, Odyssey Therapeutics, Inc.
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Andra studie-ID-nummer
- OD-001-100
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .